Safety and efficacy of once-weekly semaglutide in the initiation and switching from other GLP-1RA in patients with type 2 diabetes

Real-world Evidence for SEmaglutide Treatment in Murakami memorial hospital - RESET study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041000

Enrollment

Registered

2020-07-06

Start date

2020-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Interventions

Eligible patients are GLP-1RA naive or receiving liraglutide or dulaglutide treatment over 12 weeks before starting the trial except for insulin combination treatment with MDI or BID. Semaglutide 0.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 Diabetes Age 20 and over HbA1c over 7% GLP-1RA naive or receiving liraglutide or dulaglutide treatment over 12 weeks before starting the trial except for insulin combination treatment with MDI or BID.

Exclusion criteria

Exclusion criteria: Severe renal impairment (eGFR<30ml/min/1.73m2, end stage at CKD and dialysis) (dialysis and eGFR less than 30 ml/min)

Design outcomes

Primary

Measure	Time frame
Frequency of gastrointestinal disorders adverse events for 16 weeks Change in HbA1c, body weight, and GA from baseline to 52 weeks	—

Secondary

Measure	Time frame
Frequency of blood glucose confirmed hypoglycemia(<70 mg/dL)at 16 and 52 weeks Change in CPR and FPG at 16 and 52 weeks Effects on body composition at 16 and 52 weeks Change in HbA1c and body weight at week 16 and 52 by pretreatment and patient background	—

Countries

Japan

Contacts

Public ContactMizuho Yamabe

Murakami Memorial Hospital Department of Diabetes

mizuhoy@urban.ne.jp0848239287

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026